Core Viewpoint - 永泰生物-B (06978) has proposed a rights issue at a subscription price of HKD 2.5 per share, aiming to raise up to HKD 2.57 billion or HKD 3.08 billion depending on the conversion of convertible bonds and exercise of options [1] Group 1: Rights Issue Details - The company plans to issue up to 103 million shares, or 123 million shares if all convertible bonds are converted and options exercised, based on a record date of existing shares [1] - The rights issue is structured such that for every 5 existing shares held, shareholders will receive 1 new share [1] Group 2: Use of Proceeds - Approximately 54% of the net proceeds from the rights issue will be allocated for EAL clinical trials [1] - About 24% will be used to expand research and development expenses for other clinical indications of EAL [1] - The remaining 22% will be directed towards general operating funds of the group [1] Group 3: Trading Resumption - The company has applied to the Hong Kong Stock Exchange for the resumption of trading of its shares starting from September 22, 2025, at 9:00 AM [1]

Group 1 - The core point of the article is that Xinjiang Xintai Natural Gas Co., Ltd.'s overseas subsidiary, Zhongneng Holdings (00228.HK), plans to implement a capital restructuring and rights issue [1] - The capital restructuring includes share consolidation, capital reduction, and share split, which will not involve any cash transactions and will not change the equity structure or financial status [1] - The rights issue will be conducted at a ratio of 1 share for every 2 shares held, with a subscription price of HKD 1.57 per share, aiming to raise approximately HKD 239 million for expenses related to the Kashgar North project [1]

Core Viewpoint - Dayu Financial plans to raise a total of approximately HKD 136.7 million through a rights issue, offering shares at HKD 0.12 each [1] Group 1 - The company proposes to issue up to 1.139 billion rights shares at a ratio of 1 share for every 2 existing shares held by eligible shareholders [1] - The estimated net proceeds from the fundraising are approximately HKD 136.1 million [1] - Approximately HKD 116.1 million of the proceeds will be allocated to the group's margin financing business, while HKD 20 million will be used for general working capital [1]